Real-World Safety and Efficacy of 156 U - 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study.

ABSTRACT:

Background

The phase 3 PREEMPT clinical trials confirmed the efficacy and safety of 155 U - 195 U onabotulinumtoxinA for individuals with chronic migraine (CM) and is the licensed dose in Canada and Europe. This analysis aimed to analyze the efficacy and safety parameters of 155 U - 195 U onabotulinumtoxinA in participants with CM from the real-world REPOSE study.

Methods

REPOSE (NCT01686581) was a 2-year, prospective, observational, noninterventional, open-label study that described the real-world use of onabotulinumtoxinA in adults with CM in Europe. Participants received onabotulinumtoxinA approximately every 12 weeks and were monitored for 24 months after starting treatment. Data on participant-estimated mean headache-day frequency in the last month (MHD), Migraine-Speci

SUBMITTER: Ahmed F 

PROVIDER: S-EPMC12053858 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature